TB-500 side effects and what the literature reports
A plain-English summary of the safety record for thymosin beta-4 — what the trials show, what is missing, and where the cautions matter most.
TL;DR
- TB-500's published safety data comes mostly from animal studies and small early-phase human trials of recombinant thymosin beta-4 in cardiac, eye, and skin conditions.
- Reported side effects in those studies were mild — headache, fatigue, occasional injection-site reactions — with no major signals at the doses studied.
- The biggest honest cautions are angiogenesis-related: anyone with active or recent cancer should avoid TB-500 unless a specialist explicitly weighs the risk.
What it is
TB-500 is a synthetic fragment based on thymosin beta-4 (TB4), a 43-amino-acid protein the body makes naturally and uses for repair, cell migration, and new blood-vessel formation. The peptide sold under the TB-500 label is widely studied as a model molecule for tissue repair. As of 2026, it sits on the FDA Category 2 list, which restricts 503A compounding pharmacy access in the U.S.
How it works
Picture TB4 as a traffic cop at the site of an injury. It recruits the right cells to the right place, nudges new capillaries to sprout, and helps the repair crew migrate where they are needed. That recruitment-and-vessel-growth signal is what makes TB-500 interesting for healing — and exactly what makes it require care in anyone with cancer history. The same signal that helps a torn tendon can in principle help a tumor improve its blood supply (PubMed — thymosin beta-4 safety).
Who asks about it
People come to this topic before considering TB-500 for tendon, ligament, or post-surgical recovery, after reading enthusiastic but uncritical online content, or because they have a personal or family cancer history and want a careful read.
What the research says
Published early-phase trials of recombinant thymosin beta-4 — for ischemic heart disease, dry eye, and pressure ulcers — reported a generally well-tolerated profile at studied doses, with mild headache and injection-site irritation as the most common adverse events (ClinicalTrials.gov — thymosin beta-4). Long-term human safety data is limited. Most of what circulates online about TB-500 in muscle and tendon recovery is extrapolated from animal data, not large human trials.
What to know before considering it
The angiogenesis caution is the most important one. TB-500 is also restricted by FDA Category 2 status as of 2026, so legitimate pharmacy access is limited pending reclassification. Gray-market supply carries quality risks the published literature does not cover. Anyone considering TB-500 for an athletic recovery use should also be aware that thymosin beta-4 is on the WADA prohibited list — a relevant data point for anyone subject to drug testing.
The Halftime POV
TB-500 sits in the same honest bucket as BPC-157: interesting biology, real animal evidence, real human trials in narrow indications, and a thin long-term safety record outside those indications. We respect the cancer-history caveat, watch the regulatory clock, and prefer to wait on access until the FDA picture clears.
Related reading:
- TB-500 (thymosin beta-4): what this repair peptide is
- How TB-500 promotes angiogenesis and tissue healing
- TB-500: what Category 2 status means for access
- BPC-157 and TB-500: why these two are often discussed together
FAQ
Q: What side effects has TB-500 shown in studies? A: Reported effects in published trials of thymosin beta-4 include mild headache, fatigue, and injection-site reactions. The recombinant form has been studied in early human trials for cardiac, eye, and skin conditions with no major safety signals at studied doses.
Q: Is TB-500 safe with a cancer history? A: TB-500 promotes angiogenesis (in plain English: new blood-vessel formation), which is also part of how tumors grow. Anyone with active or recent cancer should avoid TB-500 unless a specialist explicitly weighs the risk.
Q: Is TB-500 still available in 2026? A: TB-500 is on the FDA Category 2 list, which means 503A compounding pharmacies cannot prepare it for patients. A February 2026 HHS announcement proposed returning Category 2 peptides to Category 1 pending Federal Register notice.
Disclaimer
As of 2026-05-12, TB-500 is classified by the FDA as Category 2, which means it is not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning Category 2 peptides — including TB-500 — to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What side effects has TB-500 shown in studies?
Reported effects in published trials of thymosin beta-4 include mild headache, fatigue, and injection-site reactions. The recombinant form has been studied in early human trials for cardiac, eye, and skin conditions with no major safety signals at studied doses.
Is TB-500 safe with a cancer history?
TB-500 promotes angiogenesis (in plain English: new blood-vessel formation), which is also part of how tumors grow. Anyone with active or recent cancer should avoid TB-500 unless a specialist explicitly weighs the risk.
Is TB-500 still available in 2026?
TB-500 is on the FDA Category 2 list, which means 503A compounding pharmacies cannot prepare it for patients. A February 2026 HHS announcement proposed returning Category 2 peptides to Category 1 pending Federal Register notice.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.